HomeCompareTHRX vs PLD

THRX vs PLD: Dividend Comparison 2026

THRX yields 49.20% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.53M in total portfolio value· pulled ahead in Year 8
10 years
THRX
THRX
● Live price
49.20%
Share price
$4.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$378.0K
Annual income
$75,635.59
Full THRX calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — THRX vs PLD

📍 PLD pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTHRXPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, THRX + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
THRX pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

THRX
Annual income on $10K today (after 15% tax)
$4,182.04/yr
After 10yr DRIP, annual income (after tax)
$64,290.25/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $3,973,826.16/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of THRX + PLD for your $10,000?

THRX: 50%PLD: 50%
100% PLD50/50100% THRX
Portfolio after 10yr
$3.14M
Annual income
$2,413,180.39/yr
Blended yield
76.78%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

THRX
Analyst Ratings
8
Buy
4
Hold
Consensus: Buy
Altman Z
10.0
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

THRX buys
0
PLD buys
0
No recent congressional trades found for THRX or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTHRXPLD
Forward yield49.20%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$378.0K$5.91M
Annual income after 10y$75,635.59$4,750,725.19
Total dividends collected$300.5K$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: THRX vs PLD ($10,000, DRIP)

YearTHRX PortfolioTHRX Income/yrPLD PortfolioPLD Income/yrGap
1$15,620$4,920.05$11,241$540.96+$4.4KTHRX
2$23,896$7,182.37$13,019$991.13+$10.9KTHRX
3$35,837$10,268.90$15,801$1,870.97+$20.0KTHRX
4$52,739$14,393.12$20,609$3,701.21+$32.1KTHRX
5$76,226$19,795.56$29,919$7,867.97+$46.3KTHRX
6$108,302$26,739.69$50,631$18,617.74+$57.7KTHRX
7$151,389$35,506.13$105,528$51,352.20+$45.9KTHRX
8← crossover$208,372$46,385.07$287,364$174,449.42$79.0KPLD
9$282,625$59,667.49$1,081,760$774,280.77$799.1KPLD
10$378,044$75,635.59$5,908,209$4,750,725.19$5.53MPLD

THRX vs PLD: Complete Analysis 2026

THRXStock

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Full THRX Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this THRX vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

THRX vs SCHDTHRX vs JEPITHRX vs OTHRX vs KOTHRX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.